Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Two former JHL Biotech executives, Racho Jordanov and Rose Lin, have been convicted in the US of conspiracy to commit trade secret theft and wire fraud after submitting plea agreements. Meanwhile, the company – now named Eden Biologics – has just announced a change of CEO.
The Association for Accessible Medicines has appointed former Biotechnology Innovation Organization representative Joanne Duncan as its new chief operating officer. Meanwhile, Coherus has names the new chair of its scientific advisory board, while women’s health specialist Theramex has added to its board of directors.
Teva has announced a major management reshuffle that will see North America commercial vice-president Brendan O’Grady leave the company for a new role outside the pharmaceutical industry. Revealing his replacement, Teva also unveiled further changes.
Accord has announced the appointment of a replacement for James Burt, who has stepped down from his role as executive vice-president for the Europe, Middle East and North Africa region. Meanwhile, other organizations including NeuClone, the Medicines Patent Pool, KVK Tech and Strides have also announced executive appointments.
Business development must be treated as a “strategic tool,” with partnerships and acquisitions selected based on how they fit into the company’s bigger picture, Hikma’s newly-appointed vice-president of business development for generics Patrick Genestin tells Generics Bulletin in an exclusive interview.
Steffen Wagner has taken over as Stada’s head of Germany, adding to his existing responsibilities in Europe, after Eelco Ockers stepped down from the role. Ockers’ departure comes as German generics giant Stada restructures its business to bring its branded and consumer health interests into closer alignment as part of a more streamlined model.
Hikma has named Patrick Genestin as its new head of business development for generics, bringing to the role 25 years of experience that includes most recently a 15-year stint at Sandoz. In turn, Sandoz has looked to Teva for a successor.
For the second time in as many months, Neuraxpharm has looked to Viatris to recruit a top executive to help lead the CNS specialist’s continuing expansion in Europe.
The US Association for Accessible Medicines hires for three key leadership roles, while Australia’s Generic and Biosimilar Medicines Association has named Fresenius Kabi’s director in Australia as its newest board member. Coherus’ vice president of market access and government affairs, Thomas Nusbickel, joins CorMedix as chief commercial officer, while other major firms make board changes.
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.